PL338178A1 - Pharmaceutic composition containing sole lysotaphin or in combination with an antibiotic for treating staphylococcal infections - Google Patents

Pharmaceutic composition containing sole lysotaphin or in combination with an antibiotic for treating staphylococcal infections

Info

Publication number
PL338178A1
PL338178A1 PL98338178A PL33817898A PL338178A1 PL 338178 A1 PL338178 A1 PL 338178A1 PL 98338178 A PL98338178 A PL 98338178A PL 33817898 A PL33817898 A PL 33817898A PL 338178 A1 PL338178 A1 PL 338178A1
Authority
PL
Poland
Prior art keywords
lysotaphin
antibiotic
combination
composition containing
staphylococcal infections
Prior art date
Application number
PL98338178A
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Publication of PL338178A1 publication Critical patent/PL338178A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Lysostaphin is demonstrated to be a powerful anti-staphylococcal agent suitable for parenteral administration to mammals including humans. Low dosages, on the order of 0.5 - 45 mg/kg/day are sufficient to eradicate most staphylococcal infections. Lysostaphin is also effective against bacteria of this type which have developed resistance to conventional antibiotics such as penicillins and vancomycin. Lysostaphin analogues, such as variants and related enzymes, show similar activity.
PL98338178A 1997-07-23 1998-07-21 Pharmaceutic composition containing sole lysotaphin or in combination with an antibiotic for treating staphylococcal infections PL338178A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5347097P 1997-07-23 1997-07-23

Publications (1)

Publication Number Publication Date
PL338178A1 true PL338178A1 (en) 2000-10-09

Family

ID=21984478

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98338178A PL338178A1 (en) 1997-07-23 1998-07-21 Pharmaceutic composition containing sole lysotaphin or in combination with an antibiotic for treating staphylococcal infections

Country Status (20)

Country Link
US (1) US20020006406A1 (en)
EP (1) EP1001804B1 (en)
JP (1) JP2001510805A (en)
KR (1) KR20010022237A (en)
CN (1) CN1269727A (en)
AT (1) ATE316794T1 (en)
AU (1) AU754806B2 (en)
BR (1) BR9811535A (en)
CA (1) CA2297083C (en)
DE (1) DE69833377T2 (en)
HU (1) HUP0002662A3 (en)
IL (1) IL134056A0 (en)
NO (1) NO320884B1 (en)
NZ (1) NZ502359A (en)
PL (1) PL338178A1 (en)
RU (1) RU2234940C2 (en)
SK (1) SK732000A3 (en)
TW (1) TWI235656B (en)
WO (1) WO1999004809A1 (en)
ZA (1) ZA986593B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6056954A (en) * 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
AU2001259205A1 (en) * 2000-04-28 2001-11-12 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
US7572439B2 (en) * 2002-03-26 2009-08-11 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
EP1567868A4 (en) * 2002-12-02 2008-02-06 Biosynexus Inc Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
CN1744905A (en) * 2002-12-10 2006-03-08 百敖新纳斯有限公司 Topical anti-infective formulations
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
WO2006076058A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
US7943128B2 (en) 2006-03-31 2011-05-17 The University Court Of The University Of St Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
CN101437532B (en) 2006-05-05 2013-08-21 冈戈根股份有限公司 Phage derived antimicrobial activities
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009150171A1 (en) * 2008-06-10 2009-12-17 Profos Ag Method of treatment of inflammatory diseases
US11155801B2 (en) 2013-08-06 2021-10-26 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
RU2572341C2 (en) * 2013-09-20 2016-01-10 Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) ANTIBIOTIC INA 5812, STRAIN-PRODUCER Streptomyces roseoflavus INA-As-5812 AND METHOD FOR ANTIBIOTIC OBTAINING
EP3485899A4 (en) * 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze Thermostable composition with antiviral and antibacterial activity and use thereof
US11565024B2 (en) 2017-11-16 2023-01-31 Georgia Tech Research Corporation Lysostaphin containing synthetic hydrogel carriers for bone repair
CN110917339B (en) * 2019-12-27 2023-07-07 遵义医学院附属医院 Lysostaphin gel and application thereof in MRSA (tissue-specific respiratory tract infection) wound surface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
AU623864B2 (en) * 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections

Also Published As

Publication number Publication date
TWI235656B (en) 2005-07-11
CN1269727A (en) 2000-10-11
EP1001804A1 (en) 2000-05-24
HUP0002662A2 (en) 2000-12-28
DE69833377T2 (en) 2006-11-16
NO20000314L (en) 2000-03-16
NZ502359A (en) 2005-02-25
US20020006406A1 (en) 2002-01-17
BR9811535A (en) 2000-08-29
HUP0002662A3 (en) 2003-08-28
KR20010022237A (en) 2001-03-15
ZA986593B (en) 1999-02-04
NO320884B1 (en) 2006-02-06
NO20000314D0 (en) 2000-01-21
WO1999004809A1 (en) 1999-02-04
CA2297083A1 (en) 1999-02-04
JP2001510805A (en) 2001-08-07
HU0002662D0 (en) 2000-08-28
AU754806B2 (en) 2002-11-28
CA2297083C (en) 2007-10-30
RU2234940C2 (en) 2004-08-27
EP1001804B1 (en) 2006-02-01
AU8509598A (en) 1999-02-16
SK732000A3 (en) 2001-03-12
IL134056A0 (en) 2001-04-30
ATE316794T1 (en) 2006-02-15
DE69833377D1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
PL338178A1 (en) Pharmaceutic composition containing sole lysotaphin or in combination with an antibiotic for treating staphylococcal infections
PT806941E (en) LIPOSOMIC ANTI-BACTERIAL COMPOSITIONS OF LOW RIGIDITY
WO2000057866A3 (en) Use of azalide antibiotics for the topical treatment or prevention of ocular infections
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
EA200000594A1 (en) NEW MACROLIDES
WO2002051424A8 (en) Drugs against articular failure
AU2119200A (en) Medicament
AU6484199A (en) Carbamate and carbazate ketolide antibiotics
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
MX9803692A (en) Tricyclic erythromycin derivatives.
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
ATE161265T1 (en) DERIVATIVES OF 16-MEMBER ANTIBIOTIC MACROLIDS
WO1997005870A3 (en) Use of griseofulvin for inhibiting the growth of cancers
AP2002002652A0 (en) The use of azalide antibiotic composition for treating or preventing a bacterial or protozoal infection in mammals.
NO20005332L (en) 1,6-GPS (6-O-α-D-glucopyranosyl-D-sorbit) and 1,1-GPM (1-O-α-D-glucopyranosyl-D-mannite) -containing sugar alcohol composition for use as therapeutic active substance as well as drug containing said composition
WO2000000214A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
EP0195359A3 (en) Basic monocarboxyamide derivatives of actagardine having antibiotic activity
MX9708611A (en) Dialkyltiacumicin compounds.
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
EP1671644A3 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
AUPP325398A0 (en) Improved method for eradicating h. pylori
BR0108096A (en) Method for maintaining or improving mucin synthesis
GEP20033144B (en) Hygromycin A Derivatives as Antibacterial Agents
AU5284999A (en) New injectable formulations containing ramoplanin

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)